Differentiation Syndrome, Cardiac Monitoring, and Administration of Menin Inhibitors

Opinion | Videos | October 14, 2026 Learn how clinicians recognize and manage drug-related differentiation syndrome, QTc prolongation, and dosing considerations when starting revimumab or ziftomainib in practice. Episodes in this series The moderator asks about differentiation syndrome in revumenib and ziftomenib.

One panelist covers how it presents,how often it occurs, and the need to continue corticosteroids long enough to prevent a recurrence. The moderator then asks about cardiac monitoring. The second panelist covers working with pharmacists, using the QTcF, monitoring closely and following the package insert, and having patients report any new medications.

The segment ends on administration of the medications in terms of frequency and drug interactions. Refer to individual package inserts for more information regarding dietary considerations for revumenib and ziftomenib. Related to this article